Purdue Innovation could Improve Personalized Cancer-Care Outcomes
News Aug 16, 2013
David D. Nolte, a professor in Purdue's Department of Physics, and his collaborators Ran An, a graduate student in physics, and John J. Turek in the Department of Basic Medical Sciences have created a technique called BioDynamic Imaging that measures the activity inside cancer biopsies, or samples of cells. It allows technicians to assess the efficacy of drug combinations, called regimens, on personal cancers.
"Technicians can use BioDynamic Imaging to measure tumor response to cancer therapy, such as metabolism and cell division. This can tell how well the drug is working and if there are side effects," Nolte said. "Our approach is called phenotypic testing, which is more pertinent than genetic testing because it captures the holistic response of cancer to chemotherapy."
BioDynamic Imaging tailors therapies to fit each cancer patient.
"No two cancers are alike," Nolte said. "Therefore, every patient needs his or her own selected therapy to get the best results."
Nolte said BioDynamic Imaging has other applications, including drug discovery and improving success rates for in vitro fertilization.
"BioDynamic Imaging is a new type of imaging that has broad uses and many applications," he said. "In IVF clinics, it can select the most viable embryos for implantation, improving pregnancy rates and decreasing the risk of having twins or triplets. It also can be used on a large scale to help search for new types of drugs."
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE